Ticagrelor Monotherapy vs. 12-Month Dual Anti-Platelet Therapy After Coronary Stent Implantation for ACS
The study compares the efficacy of ticagrelor monotherapy after less than 1 month of dual anti-platelet therapy (DAPT) to 12-month ticagrelor-based DAPT in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with drug-eluting stent implantation. The aim is
1 views • 19 slides
Comprehensive District Master Training for DTG in HIV Treatment Knowledge Hub
Under this program, District Master Training on the Introduction of DTG for HIV Infection Treatment is provided, supported by the Knowledge Hub. The initiative offers training materials, guidelines, and videos, accessible through the Knowledge Hub platform. Participants can register through SkillSMA
0 views • 8 slides
Insights into Garment Printing Industry Trends
Explore the evolution of garment printing businesses like PoPATL and AnaJet, the impact of DTG technology, marketing strategies, and operational efficiencies. Learn about key players like Karl Tipre and PoPATL founders Brian Wynder and Charlie Bunkley.
0 views • 42 slides
Impact of Antiretroviral Treatment on Weight and Obesity in HIV Patients
Dolutegravir (DTG) treatment has shown associations with weight gain and clinical obesity, particularly in black individuals and women. In contrast, tenofovir disoproxil fumarate (TDF) is linked to lower body weight compared to other treatments. Trials like ADVANCE and NAMSAL have provided insights
0 views • 31 slides
Ticagrelor Monotherapy vs. Ticagrelor + Aspirin in High-Risk PCI Patients: TWILIGHT-COMPLEX Study
Patients undergoing complex PCI are at high risk of ischemic events. The TWILIGHT-COMPLEX study aims to compare the safety and efficacy of ticagrelor monotherapy versus ticagrelor with aspirin in patients who completed 3 months of DAPT post-PCI. While extended DAPT may reduce ischemic events, it als
0 views • 27 slides
DTG Monotherapy in Early HIV-1 Infection: Study Overview
Study investigating the efficacy of dolutegravir (DTG) monotherapy in early HIV-1 infection showed non-inferiority compared to standard combination antiretroviral therapy (cART). The EARLY-SIMPLIFIED study involved 68 patients on DTG monotherapy and 33 on cART, with both groups achieving HIV RNA sup
0 views • 6 slides
ASPIRE Study: Switch to DTG + 3TC Virologic Outcome at W24 and W48
The ASPIRE study evaluated the efficacy of switching to DTG + 3TC in HIV patients with stable triple ART regimens. The primary endpoint was treatment failure proportion at W24, with non-inferiority demonstrated at W48. Virologic outcomes, adverse events, and patient dispositions were reported, with
0 views • 4 slides